PolyPid Ltd. (PYPD)
| Market Cap | 192.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 6.91M |
| Shares Out | 562,451 |
| EPS (ttm) | -23.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $10.40 |
| Previous Close | $10.80 |
| Change ($) | -0.40 |
| Change (%) | -3.70% |
| Day's Open | 10.80 |
| Day's Range | 10.40 - 10.80 |
| Day's Volume | 41,295 |
| 52-Week Range | 8.89 - 19.00 |
Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemi...
Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021
PETAH TIKVA, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and...
PETAH TIKVA, Israel, Nov. 24, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and ...
PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q3 2020 Results - Earnings Call Transcript
• Over 50% of p lanned 60 centers for ongoing Phase 3 SHIELD I t rial of D-PLEX 100 in a bdominal s urgery have r eceived IRB approval
PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and ...
PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and ...
PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q2 2020 Results - Earnings Call Transcript
Initiated Phase 3 SHIELD I Trial for D-PLEX100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX100 from FDA
PETAH TIKVA, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered an...
PETAH TIKVA, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered an...
PETAH TIKVA, Israel, July 27, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered an...
Polypid starts phase 3 trial in prevention of post-abdominal surgery incisional infection.
PolyPid disclosed Monday that it set terms for its initial public offering, in which the Israel-based biopharmaceutical company expects to raise up to $53.1 million. The company is offering 3...
About PYPD
PolyPid develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting ß tri-calcium phosphate granule for bone related infections applications; and BONYPID?500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/... [Read more...]
| Industry Biotechnology | IPO Date Jun 26, 2020 |
| CEO Amir Weisberg | Employees 57 |
| Stock Exchange NASDAQ | Ticker Symbol PYPD |
Analyst Forecasts
According to 3 analysts, the average rating for PolyPid stock is "Buy." The 12-month stock price forecast is 25.80, which is an increase of 148.08% from the latest price.